<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585416</url>
  </required_header>
  <id_info>
    <org_study_id>HSC2006-0099</org_study_id>
    <secondary_id>CO06801</secondary_id>
    <secondary_id>47-02-001</secondary_id>
    <nct_id>NCT00585416</nct_id>
  </id_info>
  <brief_title>Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer</brief_title>
  <official_title>A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Progen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with
      metastatic hormone refractory prostate cancer as measured by changes in PSA.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Further evaluation of phase I dosing
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Throughout and for 28 days post drug</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGC-11047</intervention_name>
    <description>CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic hormone refractory prostate cancer.

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.

          -  testosterone &lt;50ng/dL. Patients must continue primary androgen deprivation with an
             LHRH analogue if they have not undergone orchiectomy.

          -  Progressive disease after androgen deprivation.

        Exclusion Criteria:

          -  Patients whose clinical condition would make chemotherapy clearly indicated.

          -  Patients who have received systemic chemotherapy for the treatment of metastatic
             disease.

          -  Peripheral neuropathy &gt; Grade 1

          -  Prior anti-angiogenic therapy, including thalidomide.

          -  Patients with inadequate recovery from any prior surgical procedure, or patients
             having undergone any major surgical procedure or radiation within 4 weeks prior to
             study entry.

          -  Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks
             prior to enrollment.

          -  Patients with known brain metastases or history of brain metastases.

          -  History of stroke within 6 months of treatment or other significant neurological
             limitations.

          -  Patients who have received more than 2 prior investigational treatments.

          -  Uncontrolled intercurrent illness

          -  Patients with a history of a myocardial infarction within the prior 6 months or,
             hospitalizations for decompensated congestive heart failure within the prior 6 months,
             or history of significant / symptomatic cardiac arrhythmias
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Hormone Refractory</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

